Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer

O. Trédan, M. Campone, J. Jassem, R. Vyzula, B. Coudert, C. Pacilio, J. Prausova, AC. Hardy-Bessard, A. Arance, P. Mukhopadhyay, A. Aloe, H. Roché,

. 2015 ; 15 (1) : 8-15. [pub] 20140815

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16000623

BACKGROUND: Despite high initial sensitivity to chemotherapy, TNBC is associated with a poor prognosis, highlighting the need for novel therapeutic strategies. The aim of this multicenter, randomized, open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy, and the combination of ixabepilone with cetuximab, as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer. PATIENTS AND METHODS: Women were randomly assigned to receive either ixabepilone (40 mg/m(2)) every 21 days (n = 40), or ixabepilone (40 mg/m(2)) every 21 days with cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2)) once weekly (n = 39). The primary end point of the trial was to estimate the response rates of ixabepilone monotherapy and ixabepilone with cetuximab combination therapy. RESULTS: Of 79 randomized patients, 77 were treated. Based on an intent-to-treat analysis, an objective response rate of 30% (95% confidence interval [CI], 16.6-46.5) was observed in the monotherapy arm, and 35.9% (95% CI, 21.2-52.8) in the combination arm. Median progression-free survival was 4.1 months in both treatment groups. Safety findings were consistent with the known individual toxicity profiles of ixabepilone and cetuximab. Skin and subcutaneous tissue disorders were more common with combination therapy, as were discontinuations because of adverse events. CONCLUSION: Ixabepilone monotherapy and the ixabepilone and cetuximab combination demonstrated similar levels of clinical activity in first-line treatment of advanced TNBC, with a predictable safety profile. Further investigation of novel therapies for TNBC is required to improve patient outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16000623
003      
CZ-PrNML
005      
20200121094235.0
007      
ta
008      
160108s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clbc.2014.07.007 $2 doi
035    __
$a (PubMed)25218708
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Trédan, Olivier $u Centre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Lyon, France. Electronic address: olivier.tredan@lyon.unicancer.fr.
245    10
$a Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer / $c O. Trédan, M. Campone, J. Jassem, R. Vyzula, B. Coudert, C. Pacilio, J. Prausova, AC. Hardy-Bessard, A. Arance, P. Mukhopadhyay, A. Aloe, H. Roché,
520    9_
$a BACKGROUND: Despite high initial sensitivity to chemotherapy, TNBC is associated with a poor prognosis, highlighting the need for novel therapeutic strategies. The aim of this multicenter, randomized, open-label phase II trial was to assess the efficacy of ixabepilone as monotherapy, and the combination of ixabepilone with cetuximab, as first-line treatment in patients with triple-negative locally advanced nonresectable and/or metastatic breast cancer. PATIENTS AND METHODS: Women were randomly assigned to receive either ixabepilone (40 mg/m(2)) every 21 days (n = 40), or ixabepilone (40 mg/m(2)) every 21 days with cetuximab (400 mg/m(2) loading dose, followed by 250 mg/m(2)) once weekly (n = 39). The primary end point of the trial was to estimate the response rates of ixabepilone monotherapy and ixabepilone with cetuximab combination therapy. RESULTS: Of 79 randomized patients, 77 were treated. Based on an intent-to-treat analysis, an objective response rate of 30% (95% confidence interval [CI], 16.6-46.5) was observed in the monotherapy arm, and 35.9% (95% CI, 21.2-52.8) in the combination arm. Median progression-free survival was 4.1 months in both treatment groups. Safety findings were consistent with the known individual toxicity profiles of ixabepilone and cetuximab. Skin and subcutaneous tissue disorders were more common with combination therapy, as were discontinuations because of adverse events. CONCLUSION: Ixabepilone monotherapy and the ixabepilone and cetuximab combination demonstrated similar levels of clinical activity in first-line treatment of advanced TNBC, with a predictable safety profile. Further investigation of novel therapies for TNBC is required to improve patient outcomes.
650    _2
$a adenokarcinom $x farmakoterapie $x patologie $7 D000230
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a humanizované monoklonální protilátky $x aplikace a dávkování $x škodlivé účinky $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a cetuximab $7 D000068818
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a epothilony $x aplikace a dávkování $x škodlivé účinky $7 D034261
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a neoadjuvantní terapie $7 D020360
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a výsledek terapie $7 D016896
650    _2
$a triple-negativní karcinom prsu $x farmakoterapie $x patologie $7 D064726
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Campone, Mario $u Institut de Cancerologie de L Ouest, Saint Herblain, France.
700    1_
$a Jassem, Jacek $u Klinika Onkologii I Radioterapii, Uniwersyteckie, Gdansk, Poland.
700    1_
$a Vyzula, Rostislav $u Masaryk Memorial Cancer Institute, Brno, Czech Republic.
700    1_
$a Coudert, Bruno $u Crlcc G. Francois Leclerc, Dijon, France.
700    1_
$a Pacilio, Carmen $u Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy.
700    1_
$a Prausova, Jana $u Fn Motol, Praha, Czech Republic.
700    1_
$a Hardy-Bessard, Anne-Claire $u Clinique Armoricaine de Radiologie, Saint Brieuc, France.
700    1_
$a Arance, Ana $u Hospital Clinic, Barcelona, Spain. $7 gn_A_00007973
700    1_
$a Mukhopadhyay, Pralay $u Bristol-Myers Squibb, Wallingford, CT.
700    1_
$a Aloe, Alessandra $u Bristol-Myers Squibb, Rome, Italy. $7 gn_A_00004688
700    1_
$a Roché, Henri $u Institut Claudius Regaud, Toulouse, France.
773    0_
$w MED00188740 $t Clinical breast cancer $x 1938-0666 $g Roč. 15, č. 1 (2015), s. 8-15
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25218708 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160108 $b ABA008
991    __
$a 20200121094612 $b ABA008
999    __
$a ok $b bmc $g 1102904 $s 924829
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 15 $c 1 $d 8-15 $e 20140815 $i 1938-0666 $m Clinical breast cancer $n Clin Breast Cancer $x MED00188740
LZP    __
$a Pubmed-20160108

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace